For research use only. Not for therapeutic Use.
VU0155069 (CAY10593), is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays[1][2].
VU0155069 (0.5 μM, 1 h) significantly inhibits (R)-DOI (3 μM)-induced [3H]PtdBut production in MCF-7 cells[3].
Catalog Number | I010673 |
CAS Number | 1130067-06-9 |
Synonyms | N-[(2S)-1-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]naphthalene-2-carboxamide |
Molecular Formula | C26H27ClN4O2 |
Purity | ≥95% |
InChI | InChI=1S/C26H27ClN4O2/c1-17(28-25(32)20-7-6-18-4-2-3-5-19(18)14-20)16-30-12-10-22(11-13-30)31-24-9-8-21(27)15-23(24)29-26(31)33/h2-9,14-15,17,22H,10-13,16H2,1H3,(H,28,32)(H,29,33)/t17-/m0/s1 |
InChIKey | DRIMIUYGTDAQOX-KRWDZBQOSA-N |
SMILES | CC(CN1CCC(CC1)N2C3=C(C=C(C=C3)Cl)NC2=O)NC(=O)C4=CC5=CC=CC=C5C=C4 |
Reference | [1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [2]. Lewis JA, et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1916-20. [3]. Barclay Z, et al. Attenuated PLD1 association and signalling at the H452Y polymorphic form of the 5-HT(2A) receptor. Cell Signal. 2013 Apr;25(4):814-21. |